There is a moment in translational science when a biological pattern stops being an observation and becomes a decision point (for a drug program, for a clinical trial, for a patient). In my experience, metabolomics is the technology most likely to lead to that moment because it is often the most reflective of an organism’s current state. Metabolites are the end-products of active biology.